NEW YORK (GenomeWeb News) – Nanosphere today said that its second-quarter revenues jumped 160 percent year over year, but the firm fell short of Wall Street's estimate for the top line.

The Northbrook, Ill.-based molecular diagnostics firm reported preliminary Q2 revenues of $1.3 million for the three-month period ended June 30, up from $500,000 for the second quarter of 2011. However, it missed analysts' consensus estimate for revenues of $1.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.